{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:56:32Z","timestamp":1792684592185,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05549-2","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T03:11:58Z","timestamp":1765249918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Calcineurin Inhibitors: Current Role, Toxicity Management, and Future Frontiers in Immunosuppression"],"prefix":"10.1007","volume":"63","author":[{"given":"Ayush","family":"Mistry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwesha","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moitri","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumik","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arghya","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruti Bagchi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Kabsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanned Talal","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ali A.","family":"Majrashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Kamal","family":"Nagshabandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyassar Khaled","family":"Tarabulsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma M.","family":"El-Demerdash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Abdel-Daim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikram","family":"Dhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Ejim","family":"Uti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"5549_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/phpp.12600","volume":"36","author":"AC Ume","year":"2020","unstructured":"Ume AC, Pugh JM, Kemp MG, Williams CR (2020) Calcineurin inhibitor (CNI)-associated skin cancers: new insights on exploring mechanisms by which CNIs downregulate DNA repair machinery. Photodermatol Photoimmunol Photomed 36:433\u2013440. https:\/\/doi.org\/10.1111\/phpp.12600","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"5549_CR2","unstructured":"Safarini OA, Keshavamurthy C, Patel P (2025) Calcineurin inhibitors. In: StatPearls. StatPearls Publishing, Treasure Island (FL).\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558995\/"},{"key":"5549_CR3","doi-asserted-by":"publisher","first-page":"e42858","DOI":"10.1097\/MD.0000000000042858","volume":"104","author":"P Ashinze","year":"2025","unstructured":"Ashinze P, Mafua N, Banerjee S, Obafemi E, Eniola A, Emmanuel E, Edache AO, Ozioma CB, et al. (2025) Voclosporin: a comprehensive review of its role as a novel calcineurin inhibitor in the management of systemic lupus erythematosus. Medicine (Baltimore) 104:e42858. https:\/\/doi.org\/10.1097\/MD.0000000000042858","journal-title":"Medicine (Baltimore)"},{"key":"5549_CR4","doi-asserted-by":"publisher","first-page":"16592","DOI":"10.1007\/s12035-025-05149-0","volume":"62","author":"FG Kocanci","year":"2025","unstructured":"Kocanci FG, Sarban HE, Yildiz F (2025) Evaluating the neuroprotective and acetylcholinesterase inhibitory properties of four calcineurin inhibitor drugs: tacrolimus, pimecrolimus, cyclosporin A, and voclosporin. Mol Neurobiol 62:16592\u201316616. https:\/\/doi.org\/10.1007\/s12035-025-05149-0","journal-title":"Mol Neurobiol"},{"key":"5549_CR5","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3390\/cells12202440","volume":"12","author":"A Kale","year":"2023","unstructured":"Kale A, Shelke V, Lei Y, Gaikwad AB, Anders H-J (2023) Voclosporin: unique chemistry, pharmacology and toxicity profile, and possible options for implementation into the management of lupus nephritis. Cells 12:2440. https:\/\/doi.org\/10.3390\/cells12202440","journal-title":"Cells"},{"key":"5549_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Kuypers DRJ, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4:481\u2013508. https:\/\/doi.org\/10.2215\/CJN.04800908","journal-title":"Clin J Am Soc Nephrol"},{"key":"5549_CR7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","volume":"321","author":"BD Kahan","year":"1989","unstructured":"Kahan BD (1989) Cyclosporine. N Engl J Med 321:1725\u20131738. https:\/\/doi.org\/10.1056\/NEJM198912213212507","journal-title":"N Engl J Med"},{"key":"5549_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/DDDT.S149340","volume":"12","author":"T Xia","year":"2018","unstructured":"Xia T, Zhu S, Wen Y, Gao S, Li M, Tao X, Zhang F, Chen W (2018) Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis. Drug Des Devel Ther 12:417\u2013428. https:\/\/doi.org\/10.2147\/DDDT.S149340","journal-title":"Drug Des Devel Ther"},{"key":"5549_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/diagnostics15030284","volume":"15","author":"L Popovi\u0107","year":"2025","unstructured":"Popovi\u0107 L, Bulum T (2025) New onset diabetes after organ transplantation: risk factors, treatment, and consequences. Diagnostics 15:284. https:\/\/doi.org\/10.3390\/diagnostics15030284","journal-title":"Diagnostics"},{"key":"5549_CR10","unstructured":"Solhjoo M, Kumar SC (2025) New onset diabetes after transplant. In: StatPearls. StatPearls Publishing, Treasure Island (FL).\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544220\/"},{"key":"5549_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00924-z","volume":"13","author":"Y He","year":"2020","unstructured":"He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, et al. (2020) Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol 13:103. https:\/\/doi.org\/10.1186\/s13045-020-00924-z","journal-title":"J Hematol Oncol"},{"key":"5549_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70401","volume":"6","author":"G Fan","year":"2025","unstructured":"Fan G, Chen S, Zhang Q, Yu N, Shen Z, Liu Z, Guo W, Tang Z, et al. (2025) Proteolysis-targeting chimera (PROTAC): current applications and future directions. MedComm 6:e70401. https:\/\/doi.org\/10.1002\/mco2.70401","journal-title":"MedComm"},{"key":"5549_CR13","unstructured":"Tapia C, Nessel TA, Zito PM (2025) Cyclosporine. In: StatPearls. StatPearls Publishing, Treasure Island (FL).\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482450\/"},{"key":"5549_CR14","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/ehf2.12749","volume":"7","author":"Y Shiraishi","year":"2020","unstructured":"Shiraishi Y, Amiya E, Hatano M, Katsuki T, Bujo C, Tsuji M, Nitta D, Maki H, et al. (2020) Impact of tacrolimus versus cyclosporin A on renal function during the first year after heart transplant. ESC Heart Fail 7:1842\u20131849. https:\/\/doi.org\/10.1002\/ehf2.12749","journal-title":"ESC Heart Fail"},{"key":"5549_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01074","author":"Y-C Lin","year":"2019","unstructured":"Lin Y-C, Tsai C-S, Li I-H, Tsai Y-T, Huang T-Y, Lee K-F, Lin C-S, Shih J-H, et al. (2019) Transplant recipients using tacrolimus had higher utilization of healthcare services than those receiving cyclosporine in Taiwan. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.01074","journal-title":"Front Pharmacol"},{"key":"5549_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40620-020-00956-1","volume":"34","author":"I Faravelli","year":"2021","unstructured":"Faravelli I, Velardo D, Podest\u00e0 MA, Ponticelli C (2021) Immunosuppression-related neurological disorders in kidney transplantation. J Nephrol 34:539\u2013555. https:\/\/doi.org\/10.1007\/s40620-020-00956-1","journal-title":"J Nephrol"},{"key":"5549_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/TRRM.S183382","volume":"11","author":"AG Cuenca","year":"2019","unstructured":"Cuenca AG, Yeh H (2019) Improving patient outcomes following pediatric liver transplant: current perspectives. Transpl Res Risk Manag 11:69\u201378. https:\/\/doi.org\/10.2147\/TRRM.S183382","journal-title":"Transpl Res Risk Manag"},{"key":"5549_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103602","volume":"14","author":"AY Lee","year":"2025","unstructured":"Lee AY, Jeong J, Heo K-N, Park S, Ah Y-M, Han JM, Lee J-Y, Min SI (2025) Complications associated with immunosuppressive agents in solid organ transplant recipients: a nationwide analysis. J Clin Med 14:3602. https:\/\/doi.org\/10.3390\/jcm14103602","journal-title":"J Clin Med"},{"key":"5549_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/uro1030018","volume":"1","author":"R Ahmed","year":"2021","unstructured":"Ahmed R, Hassan Z, Haseeb A, Masood A, Ali I (2021) Multiple adverse drug reactions to calcineurin inhibitors in a renal transplant patient. Uro 1:180\u2013186. https:\/\/doi.org\/10.3390\/uro1030018","journal-title":"Uro"},{"key":"5549_CR20","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1016\/j.transproceed.2023.09.027","volume":"55","author":"AA Feist","year":"2023","unstructured":"Feist AA, Mariski M, Awdishu L, Bremer M, Yung G, Jung C, Golts E, Afshar K (2023) Sirolimus long-term tolerability and impact on kidney function in lung transplantation: a single-center experience. Transplant Proc 55:2470\u20132477. https:\/\/doi.org\/10.1016\/j.transproceed.2023.09.027","journal-title":"Transplant Proc"},{"key":"5549_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115167","volume":"165","author":"Y Lin","year":"2023","unstructured":"Lin Y, Song Y, Zhang Y, Shi M, Hou A, Han S (2023) NFAT signaling dysregulation in cancer: emerging roles in cancer stem cells. Biomed Pharmacother 165:115167. https:\/\/doi.org\/10.1016\/j.biopha.2023.115167","journal-title":"Biomed Pharmacother"},{"key":"5549_CR22","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s12035-023-03580-9","volume":"61","author":"L Singh","year":"2024","unstructured":"Singh L, Bhatti R (2024) Signaling pathways involved in the neuroprotective effect of osthole: evidence and mechanisms. Mol Neurobiol 61:1100\u20131118. https:\/\/doi.org\/10.1007\/s12035-023-03580-9","journal-title":"Mol Neurobiol"},{"key":"5549_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/vaccines11020270","volume":"11","author":"H Ahmad","year":"2023","unstructured":"Ahmad H, Zia B, Husain H, Husain A (2023) Recent advances in PROTAC-based antiviral strategies. Vaccines 11:270. https:\/\/doi.org\/10.3390\/vaccines11020270","journal-title":"Vaccines"},{"key":"5549_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/ndt\/gfad161","volume":"39","author":"G Capolongo","year":"2023","unstructured":"Capolongo G, Damiano S, Suzumoto Y, Zacchia M, Rizzo M, Zona E, Pollastro RM, Simeoni M, et al. (2023) Cyclosporin-induced hypertension is associated with the up-regulation of Na+-K+-2Cl\u2212 cotransporter (NKCC2). Nephrol Dial Transplant 39:297\u2013304. https:\/\/doi.org\/10.1093\/ndt\/gfad161","journal-title":"Nephrol Dial Transplant"},{"key":"5549_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/fermentation10120645","volume":"10","author":"C Barreiro","year":"2024","unstructured":"Barreiro C, Iba\u00f1ez A, Garrido-Chamorro S, Barredo JL (2024) The immunosuppressant tacrolimus (FK506) facing the 21st century: past findings, present applications and future trends. Fermentation 10:645. https:\/\/doi.org\/10.3390\/fermentation10120645","journal-title":"Fermentation"},{"key":"5549_CR26","doi-asserted-by":"publisher","unstructured":"Sammaritano LR, Askanase A, Bermas BL, Dall\u2019Era M, Duarte-Garc\u00eda A, Hiraki LT, Rovin BH, Son MBF, et al 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. Hoboken NJ. 77, 1115\u20131135 (2025). https:\/\/doi.org\/10.1002\/art.43212","DOI":"10.1002\/art.43212"},{"key":"5549_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147683","volume":"131","author":"S Otsuka","year":"2021","unstructured":"Otsuka S, Melis N, Gaida MM, Dutta D, Weigert R, Ashwell JD (2021) Calcineurin inhibitors suppress acute graft-versus-host disease via NFAT-independent inhibition of T cell receptor signaling. J Clin Invest 131:e147683. https:\/\/doi.org\/10.1172\/JCI147683","journal-title":"J Clin Invest"},{"key":"5549_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00210","author":"LA Mortensen","year":"2017","unstructured":"Mortensen LA, Bistrup C, Thiesson HC (2017) Does mineralocorticoid receptor antagonism prevent calcineurin inhibitor-induced nephrotoxicity? Front Med. https:\/\/doi.org\/10.3389\/fmed.2017.00210","journal-title":"Front Med"},{"key":"5549_CR29","doi-asserted-by":"publisher","first-page":"F336","DOI":"10.1152\/ajprenal.00262.2020","volume":"320","author":"AC Ume","year":"2021","unstructured":"Ume AC, Wenegieme T-Y, Williams CR (2021) Calcineurin inhibitors: a double-edged sword. Am J Physiol Renal Physiol 320:F336\u2013F341. https:\/\/doi.org\/10.1152\/ajprenal.00262.2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"5549_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107623","volume":"215","author":"S Annett","year":"2020","unstructured":"Annett S, Moore G, Robson T (2020) FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention. Pharmacol Ther 215:107623. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107623","journal-title":"Pharmacol Ther"},{"key":"5549_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4899-0987-9_10","volume-title":"Mechanisms of lymphocyte activation and immune regulation V: molecular basis of signal transduction","author":"BA Premack","year":"1994","unstructured":"Premack BA, Gardner P (1994) Properties of Ca currents activated by T cell receptor signaling. In: Gupta S, Paul WE, DeFranco A, Perlmutter RM (eds) Mechanisms of lymphocyte activation and immune regulation V: molecular basis of signal transduction. Springer, US, Boston, MA, pp 91\u2013102"},{"key":"5549_CR32","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41467-022-28429-y","volume":"13","author":"R-G Xie","year":"2022","unstructured":"Xie R-G, Chu W-G, Liu D-L, Wang X, Ma S-B, Wang F, Wang F-D, Lin Z, et al. (2022) Presynaptic NMDARs on spinal nociceptor terminals state-dependently modulate synaptic transmission and pain. Nat Commun 13:728. https:\/\/doi.org\/10.1038\/s41467-022-28429-y","journal-title":"Nat Commun"},{"key":"5549_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109570","volume":"234","author":"G Olivero","year":"2023","unstructured":"Olivero G, Grilli M, Marchi M, Pittaluga A (2023) Metamodulation of presynaptic NMDA receptors: new perspectives for pharmacological interventions. Neuropharmacology 234:109570. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109570","journal-title":"Neuropharmacology"},{"key":"5549_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102149","volume":"55","author":"X Huang","year":"2024","unstructured":"Huang X, Li X, Tay A (2024) Advances in techniques to characterize cell-nanomaterial interactions (CNI). Nano Today 55:102149. https:\/\/doi.org\/10.1016\/j.nantod.2024.102149","journal-title":"Nano Today"},{"key":"5549_CR35","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41467-021-23133-9","volume":"12","author":"B Compans","year":"2021","unstructured":"Compans B, Camus C, Kallergi E, Sposini S, Martineau M, Butler C, Kechkar A, Klaassen RV, et al. (2021) NMDAR-dependent long-term depression is associated with increased short term plasticity through autophagy mediated loss of PSD-95. Nat Commun 12:2849. https:\/\/doi.org\/10.1038\/s41467-021-23133-9","journal-title":"Nat Commun"},{"key":"5549_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212366","volume":"25","author":"R Tumdam","year":"2024","unstructured":"Tumdam R, Hussein Y, Garin-Shkolnik T, Stern S (2024) NMDA receptors in neurodevelopmental disorders: pathophysiology and disease models. Int J Mol Sci 25:12366. https:\/\/doi.org\/10.3390\/ijms252212366","journal-title":"Int J Mol Sci"},{"key":"5549_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2021.722323","volume":"15","author":"MM Pal","year":"2021","unstructured":"Pal MM (2021) Glutamate: the master neurotransmitter and its implications in chronic stress and mood disorders. Front Hum Neurosci 15:722323. https:\/\/doi.org\/10.3389\/fnhum.2021.722323","journal-title":"Front Hum Neurosci"},{"key":"5549_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108749","volume":"197","author":"Q-Y Chen","year":"2021","unstructured":"Chen Q-Y, Li X-H, Zhuo M (2021) NMDA receptors and synaptic plasticity in the anterior cingulate cortex. Neuropharmacology 197:108749. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108749","journal-title":"Neuropharmacology"},{"key":"5549_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1068472","author":"S Lutzu","year":"2023","unstructured":"Lutzu S, Alvi\u00f1a K, Puente N, Grandes P, Castillo PE (2023) Target cell-specific plasticity rules of NMDA receptor-mediated synaptic transmission in the hippocampus. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2023.1068472","journal-title":"Front Cell Neurosci"},{"key":"5549_CR40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40262-024-01368-1","volume":"63","author":"JEM van Dommelen","year":"2024","unstructured":"van Dommelen JEM, Grootjans H, Uijtendaal EV, Ruigrok D, Luijk B, van Luin M, Bult W, de Lange DW, et al. (2024) Tacrolimus variability and clinical outcomes in the early post-lung transplantation period: oral versus continuous intravenous administration. Clin Pharmacokinet 63:683\u2013693. https:\/\/doi.org\/10.1007\/s40262-024-01368-1","journal-title":"Clin Pharmacokinet"},{"key":"5549_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14145152","volume":"14","author":"MA Khan","year":"2025","unstructured":"Khan MA, Mehmood M, EL Azzazi H, Shaikh S, Bhasin-Chhabra B, Gudsoorkar P, Nair SS, Kodali L, et al. (2025) Immune checkpoint inhibitors and allograft rejection risk: emerging evidence regarding their use in kidney transplant recipients. J Clin Med 14:5152. https:\/\/doi.org\/10.3390\/jcm14145152","journal-title":"J Clin Med"},{"key":"5549_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.714","volume":"5","author":"R Wang","year":"2024","unstructured":"Wang R, Lan C, Benlagha K, Camara NOS, Miller H, Kubo M, Heegaard S, Lee P, et al. (2024) The interaction of innate immune and adaptive immune system. MedComm 5:e714. https:\/\/doi.org\/10.1002\/mco2.714","journal-title":"MedComm"},{"key":"5549_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00195","author":"Y-J Park","year":"2020","unstructured":"Park Y-J, Yoo S-A, Kim M, Kim W-U (2020) The role of calcium\u2013calcineurin\u2013NFAT signaling pathway in health and autoimmune diseases. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00195","journal-title":"Front Immunol"},{"key":"5549_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2023.105015","volume":"16","author":"C Wang","year":"2023","unstructured":"Wang C, Zhang Y, Yang S, Xing D (2023) Recent advances of PROTACs technology in neurodegenerative diseases. Arab J Chem 16:105015. https:\/\/doi.org\/10.1016\/j.arabjc.2023.105015","journal-title":"Arab J Chem"},{"key":"5549_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8070977","volume":"8","author":"L Cavagna","year":"2020","unstructured":"Cavagna L, Seminari E, Zanframundo G, Gregorini M, Di Matteo A, Rampino T, Montecucco C, Pelenghi S, et al. (2020) Calcineurin inhibitor-based immunosuppression and COVID-19: results from a multidisciplinary cohort of patients in Northern Italy. Microorganisms 8:977. https:\/\/doi.org\/10.3390\/microorganisms8070977","journal-title":"Microorganisms"},{"key":"5549_CR46","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3389\/fphar.2020.01333","volume":"11","author":"TS Schoot","year":"2020","unstructured":"Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ (2020) Immunosuppressive drugs and COVID-19: a review. Front Pharmacol 11:1333. https:\/\/doi.org\/10.3389\/fphar.2020.01333","journal-title":"Front Pharmacol"},{"key":"5549_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/0886022X.2021.1876730","volume":"43","author":"A Daoud","year":"2021","unstructured":"Daoud A, Alqassieh A, Alkhader D, Posadas Salas MA, Rao V, F\u00fcl\u00f6p T, Soliman KM (2021) Immunosuppression in kidney transplant recipients with COVID-19 infection \u2013 where do we stand and where are we heading? Ren Fail 43:273\u2013280. https:\/\/doi.org\/10.1080\/0886022X.2021.1876730","journal-title":"Ren Fail"},{"key":"5549_CR48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2012.02.004","volume":"321","author":"A Basu","year":"2012","unstructured":"Basu A, Liu T, Banerjee P, Flynn E, Zurakowski D, Datta D, Viklicky O, Gasser M, et al. (2012) Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. Cancer Lett 321:179\u2013186. https:\/\/doi.org\/10.1016\/j.canlet.2012.02.004","journal-title":"Cancer Lett"},{"key":"5549_CR49","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/17401","volume":"397","author":"M Hojo","year":"1999","unstructured":"Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530\u2013534. https:\/\/doi.org\/10.1038\/17401","journal-title":"Nature"},{"key":"5549_CR50","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.21873\/invivo.12880","volume":"36","author":"M Satake","year":"2022","unstructured":"Satake M, Sakuraba H, Hiraga H, Yoshida S, Akemoto Y, Ota S, Murai Y, Hasui K, et al. (2022) Tacrolimus up-regulates expression of TGF\u03b2 receptor type II via ERK, providing protection against intestinal epithelial injury. In Vivo 36:1684\u20131693. https:\/\/doi.org\/10.21873\/invivo.12880","journal-title":"In Vivo"},{"key":"5549_CR51","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.3390\/curroncol30060421","volume":"30","author":"L Todeschini","year":"2023","unstructured":"Todeschini L, Cristin L, Martinino A, Mattia A, Agnes S, Giovinazzo F (2023) The role of mTOR inhibitors after liver transplantation for hepatocellular carcinoma. Curr Oncol 30:5574\u20135592. https:\/\/doi.org\/10.3390\/curroncol30060421","journal-title":"Curr Oncol"},{"key":"5549_CR52","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.intimp.2019.01.035","volume":"69","author":"N Saber-Moghaddam","year":"2019","unstructured":"Saber-Moghaddam N, Nomani H, Sahebkar A, Johnston TP, Mohammadpour AH (2019) The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation. Int Immunopharmacol 69:150\u2013158. https:\/\/doi.org\/10.1016\/j.intimp.2019.01.035","journal-title":"Int Immunopharmacol"},{"key":"5549_CR53","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.3390\/curroncol30060430","volume":"30","author":"A Kulbat","year":"2023","unstructured":"Kulbat A, Richter K, Stefura T, Ko\u0142odziej-Rzepa M, Kisielewski M, Wojewoda T, Wysocki WM (2023) Systematic review of calcineurin inhibitors and incidence of skin malignancies after kidney transplantation in adult patients: a study of 309,551 cases. Curr Oncol 30:5727\u20135737. https:\/\/doi.org\/10.3390\/curroncol30060430","journal-title":"Curr Oncol"},{"key":"5549_CR54","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3389\/fmicb.2019.02853","volume":"10","author":"Y Li","year":"2019","unstructured":"Li Y, Jiao P, Li Y, Gong Y, Chen X, Sun S (2019) The synergistic antifungal effect and potential mechanism of D-penicillamine combined with fluconazole against Candida albicans. Front Microbiol 10:2853. https:\/\/doi.org\/10.3389\/fmicb.2019.02853","journal-title":"Front Microbiol"},{"key":"5549_CR55","doi-asserted-by":"publisher","unstructured":"de Lima Silva MG, de Lima LF, Alencar Fonseca VJ, Santos da Silva LY, Calixto Donelardy AC, de Almeida RS, de Morais Oliveira-Tintino CD, Pereira Bezerra Martins AO, Ribeiro-Filho J, Bezerra Morais-Braga MF, Tintino SR. Enhancing the Antifungal Efficacy of Fluconazole with a Diterpene: Abietic Acid as a Promising Adjuvant to Combat Antifungal Resistance in Candida spp. Antibiotics. 2023 12(11):1565. https:\/\/doi.org\/10.3390\/antibiotics12111565","DOI":"10.3390\/antibiotics12111565"},{"key":"5549_CR56","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1016\/j.radcr.2024.06.015","volume":"19","author":"RY Nasr","year":"2024","unstructured":"Nasr RY, Othman MA (2024) Calcineurin inhibitor-induced pain syndrome (CIPS) affects the hips in a renal transplant recipient: a case report. Radiol Case Rep 19:4024\u20134028. https:\/\/doi.org\/10.1016\/j.radcr.2024.06.015","journal-title":"Radiol Case Rep"},{"key":"5549_CR57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13075-025-03661-1","volume":"27","author":"W Bai","year":"2025","unstructured":"Bai W, Luo H, Wu H, Duan X, Xu J, Zhao C, Zou Q, Shi X, et al. (2025) Effectiveness and safety of tacrolimus in systemic lupus erythematosus with various clinical manifestations: a retrospective real-world study. Arthritis Res Ther 27:198. https:\/\/doi.org\/10.1186\/s13075-025-03661-1","journal-title":"Arthritis Res Ther"},{"key":"5549_CR58","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3892\/br.2025.2023","volume":"23","author":"X Li","year":"2025","unstructured":"Li X, Zhou J, Liu Y (2025) Efficacy of tacrolimus and other immunosuppressants in the treatment of systemic lupus erythematosus: a systematic review and meta-analysis. Biomed Rep 23:145. https:\/\/doi.org\/10.3892\/br.2025.2023","journal-title":"Biomed Rep"},{"key":"5549_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1331800","author":"M Wang","year":"2024","unstructured":"Wang M, Zhou J, Niu Q, Wang H (2024) Mechanism of tacrolimus in the treatment of lupus nephritis. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1331800","journal-title":"Front Pharmacol"},{"key":"5549_CR60","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.2147\/DDDT.S528565","volume":"19","author":"Y Han","year":"2025","unstructured":"Han Y, Yang F, Zhou L, Yang J, Yang Y, Wang Y, Qiu L, Zhang Y, et al. (2025) Efficacy and long-term outcomes of tacrolimus versus cyclophosphamide and mycophenolate mofetil in the management of pediatric IgA vasculitis nephritis: a cohort study in single-center. Drug Des Devel Ther 19:6413\u20136422. https:\/\/doi.org\/10.2147\/DDDT.S528565","journal-title":"Drug Des Devel Ther"},{"key":"5549_CR61","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","volume":"79","author":"CC Mok","year":"2020","unstructured":"Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL (2020) Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis 79:1070\u20131076. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217178","journal-title":"Ann Rheum Dis"},{"key":"5549_CR62","doi-asserted-by":"publisher","first-page":"e937201\u20131","DOI":"10.12659\/AJCR.937201","volume":"23","author":"I Kurihara","year":"2022","unstructured":"Kurihara I, Terai C, Yabe H, Sugawara H (2022) Tacrolimus induction therapy for nephrotic syndrome caused by minimal mesangial lupus nephritis with lupus podocytopathy: a case-based review. Am J Case Rep 23:e937201-1-e937201-4. https:\/\/doi.org\/10.12659\/AJCR.937201","journal-title":"Am J Case Rep"},{"key":"5549_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-024-00386-8","volume":"64","author":"ETdos Reis-Neto","year":"2024","unstructured":"Reis-Neto ETdos, Seguro LPC, Sato EI, Borba EF, Klumb EM, Costallat LTL, Medeiros MMdasC, Bonf\u00e1 E, et al. (2024) II Brazilian society of rheumatology consensus for lupus nephritis diagnosis and treatment. Adv Rheumatol 64:48. https:\/\/doi.org\/10.1186\/s42358-024-00386-8","journal-title":"Adv Rheumatol"},{"key":"5549_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101589","volume":"298","author":"DE Yilmaz","year":"2022","unstructured":"Yilmaz DE, Kirschner K, Demirci H, Himmerkus N, Bachmann S, Mutig K (2022) Immunosuppressive calcineurin inhibitor cyclosporine A induces proapoptotic endoplasmic reticulum stress in renal tubular cells. J Biol Chem 298:101589. https:\/\/doi.org\/10.1016\/j.jbc.2022.101589","journal-title":"J Biol Chem"},{"key":"5549_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031465","volume":"7","author":"K Tsuda","year":"2012","unstructured":"Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, Nakanishi T, Kakeda M, et al. (2012) Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of na\u00efve T cells into cytokine-producing mature T cells. PLoS ONE 7:e31465. https:\/\/doi.org\/10.1371\/journal.pone.0031465","journal-title":"PLoS ONE"},{"key":"5549_CR66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/B978-1-4160-3661-6.00049-3","volume-title":"Canine and Feline Gastroenterology","author":"RK Sellon","year":"2013","unstructured":"Sellon RK (2013) Chapter 49 - immunosuppressive drugs. In: Washabau RJ, Day MJ (eds) Canine and Feline Gastroenterology. W.B. Saunders, Saint Louis, pp 517\u2013521"},{"key":"5549_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/563709","volume":"2012","author":"C Rodriguez-Cerdeira","year":"2012","unstructured":"Rodriguez-Cerdeira C, Sanchez-Blanco E, Molares-Vila A (2012) Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases. Mediators Inflamm 2012:563709. https:\/\/doi.org\/10.1155\/2012\/563709","journal-title":"Mediators Inflamm"},{"key":"5549_CR68","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/pds.3199","volume":"21","author":"CG Rowan","year":"2012","unstructured":"Rowan CG, Brunelli SM, Munson J, Flory J, Reese PP, Hennessy S, Lewis J, Mines D, et al. (2012) Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf 21:494\u2013506. https:\/\/doi.org\/10.1002\/pds.3199","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5549_CR69","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.3390\/cimb46070377","volume":"46","author":"KE Jones","year":"2024","unstructured":"Jones KE, Hayden SL, Meyer HR, Sandoz JL, Arata WH, Dufrene K, Ballaera C, Lopez Torres Y, et al. (2024) The evolving role of calcium channel blockers in hypertension management: pharmacological and clinical considerations. Curr Issues Mol Biol 46:6315\u20136327. https:\/\/doi.org\/10.3390\/cimb46070377","journal-title":"Curr Issues Mol Biol"},{"key":"5549_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-019-0103-x","volume":"6","author":"M Go\u017adzik","year":"2019","unstructured":"Go\u017adzik M, P\u0142uciennik A, Zawiasa-Bryszewska A, Nowicka M, Nowicka Z, W\u0105growska-Danilewicz M, Kurnatowska I (2019) Acute kidney injury following exposure to calcineurin inhibitors in a patient with idiopathic membranous nephropathy. Drug Saf - Case Rep 6:9. https:\/\/doi.org\/10.1007\/s40800-019-0103-x","journal-title":"Drug Saf - Case Rep"},{"key":"5549_CR71","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/japtr.JAPTR_336_18","volume":"10","author":"MS Al-Naimi","year":"2019","unstructured":"Al-Naimi MS, Rasheed HA, Hussien NR, Al-Kuraishy HM, Al-Gareeb AI (2019) Nephrotoxicity: role and significance of renal biomarkers in the early detection of acute renal injury. J Adv Pharm Technol Res 10:95\u201399. https:\/\/doi.org\/10.4103\/japtr.JAPTR_336_18","journal-title":"J Adv Pharm Technol Res"},{"key":"5549_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/8145388","volume":"2024","author":"S Chai","year":"2024","unstructured":"Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F (2024) Comparison of GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors as an add-on drug to insulin combined with oral hypoglycemic drugs: umbrella review. J Diabetes Res 2024:8145388. https:\/\/doi.org\/10.1155\/2024\/8145388","journal-title":"J Diabetes Res"},{"key":"5549_CR73","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/biomedicines13040929","volume":"13","author":"M Pittappilly","year":"2025","unstructured":"Pittappilly M, Sharshir M, Paramesh A (2025) Chronic allograft nephropathy\u2014a narrative review of its pathogenesis, diagnosis, and evolving management strategies. Biomedicines 13:929. https:\/\/doi.org\/10.3390\/biomedicines13040929","journal-title":"Biomedicines"},{"key":"5549_CR74","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/j.ackd.2015.01.002","volume":"22","author":"AP Rossi","year":"2015","unstructured":"Rossi AP, Vella JP (2015) Hypertension, living kidney donors, and transplantation: where are we today? Adv Chronic Kidney Dis 22:154\u2013164. https:\/\/doi.org\/10.1053\/j.ackd.2015.01.002","journal-title":"Adv Chronic Kidney Dis"},{"key":"5549_CR75","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/TCRM.S142348","volume":"13","author":"F-C Liu","year":"2017","unstructured":"Liu F-C, Lin H-T, Lin J-R, Yu H-P (2017) Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients. Ther Clin Risk Manag 13:1043\u20131051. https:\/\/doi.org\/10.2147\/TCRM.S142348","journal-title":"Ther Clin Risk Manag"},{"key":"5549_CR76","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.34067\/KID.0004042021","volume":"2","author":"F Aziz","year":"2021","unstructured":"Aziz F (2021) New onset diabetes mellitus after transplant: the challenge continues. Kidney360 2:1212. https:\/\/doi.org\/10.34067\/KID.0004042021","journal-title":"Kidney360"},{"key":"5549_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144268","volume":"13","author":"C Solano","year":"2024","unstructured":"Solano C, Corrales M, Panthier F, Doizi S, Traxer O (2024) Comprehensive approaches to urolithiasis in renal transplants: a narrative review. J Clin Med 13:4268. https:\/\/doi.org\/10.3390\/jcm13144268","journal-title":"J Clin Med"},{"key":"5549_CR78","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13104-017-2477-0","volume":"10","author":"B Cheunsuchon","year":"2017","unstructured":"Cheunsuchon B, Sritippayawan S (2017) Successful treatment of early allograft dysfunction with cinacalcet in a patient with nephrocalcinosis caused by severe hyperparathyroidism: a case report. BMC Res Notes 10:153. https:\/\/doi.org\/10.1186\/s13104-017-2477-0","journal-title":"BMC Res Notes"},{"key":"5549_CR79","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.935607","volume":"27","author":"OL Griffis","year":"2022","unstructured":"Griffis OL, Thai SQ, Allison C, Baetz B, Mohammed A (2022) The association between tacrolimus levels and hyperkalemia in allograft recipients who underwent heart or lung transplantation in New Orleans, USA between 2013 and 2019: a single-center retrospective study. Ann Transplant 27:e935607\u20131-e935607-8. https:\/\/doi.org\/10.12659\/AOT.935607","journal-title":"Ann Transplant"},{"key":"5549_CR80","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.ihj.2024.01.004","volume":"76","author":"A Mehta","year":"2024","unstructured":"Mehta A (2024) Managing dyslipidemia in solid organ transplant patients. Indian Heart J 76:S93\u2013S95. https:\/\/doi.org\/10.1016\/j.ihj.2024.01.004","journal-title":"Indian Heart J"},{"key":"5549_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144080","volume":"11","author":"G Iannuzzo","year":"2022","unstructured":"Iannuzzo G, Cuomo G, Di Lorenzo A, Tripaldella M, Mallardo V, Iaccarino Idelson P, Sagnelli C, Sica A, et al. (2022) Dyslipidemia in transplant patients: which therapy? J Clin Med 11:4080. https:\/\/doi.org\/10.3390\/jcm11144080","journal-title":"J Clin Med"},{"key":"5549_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.981838","author":"A Elezaby","year":"2022","unstructured":"Elezaby A, Dexheimer R, Sallam K (2022) Cardiovascular effects of immunosuppression agents. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2022.981838","journal-title":"Front Cardiovasc Med"},{"key":"5549_CR83","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.3390\/jcm12216935","volume":"12","author":"B Opa\u0142ka","year":"2023","unstructured":"Opa\u0142ka B, \u017bo\u0142nierczuk M, Grabowska M (2023) Immunosuppressive agents\u2014effects on the cardiovascular system and selected metabolic aspects: a review. J Clin Med 12:6935. https:\/\/doi.org\/10.3390\/jcm12216935","journal-title":"J Clin Med"},{"key":"5549_CR84","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149934","author":"NM Carter","year":"2021","unstructured":"Carter NM, Pomerantz JL (2021) Calcineurin inhibitors target Lck activation in graft-versus-host disease. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI149934","journal-title":"J Clin Invest"},{"key":"5549_CR85","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13555-019-00346-x","volume":"10","author":"S Sukanjanapong","year":"2019","unstructured":"Sukanjanapong S, Thongtan D, Kanokrungsee S, Suchonwanit P, Chanprapaph K (2019) A comparison of azathioprine and mycophenolate mofetil as adjuvant drugs in patients with pemphigus: a retrospective cohort study. Dermatol Ther 10:179\u2013189. https:\/\/doi.org\/10.1007\/s13555-019-00346-x","journal-title":"Dermatol Ther"},{"key":"5549_CR86","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1186\/s12876-025-04206-1","volume":"25","author":"AM Ali","year":"2025","unstructured":"Ali AM, Abdelrahim ME, AbdelMagid AM (2025) Mycophenolate mofetil versus azathioprine as a first-line treatment for autoimmune hepatitis: a comparative systematic review and meta-analysis. BMC Gastroenterol 25:613. https:\/\/doi.org\/10.1186\/s12876-025-04206-1","journal-title":"BMC Gastroenterol"},{"key":"5549_CR87","doi-asserted-by":"publisher","unstructured":"Hahn D, Hodson EM, Hamiwka LA, Lee VW, Chapman JR, Craig JC, Webster AC (2019) Target of rapamycin inhibitors (TOR\u2010I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2019, CD004290 (2019). https:\/\/doi.org\/10.1002\/14651858.CD004290.pub3","DOI":"10.1002\/14651858.CD004290.pub3"},{"key":"5549_CR88","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/s12872-023-03547-7","volume":"23","author":"D Kanda","year":"2023","unstructured":"Kanda D, Takumi T, Tokushige A, Ikeda Y, Ohishi M (2023) Different effects of medications for hypertension on renal function between patients with and without diabetes mellitus undergoing percutaneous coronary intervention: a retrospective single-center cohort study. BMC Cardiovasc Disord 23:509. https:\/\/doi.org\/10.1186\/s12872-023-03547-7","journal-title":"BMC Cardiovasc Disord"},{"key":"5549_CR89","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","volume":"14","author":"J Klawitter","year":"2015","unstructured":"Klawitter J, Nashan B, Christians U (2015) Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 14:1055\u20131070. https:\/\/doi.org\/10.1517\/14740338.2015.1040388","journal-title":"Expert Opin Drug Saf"},{"key":"5549_CR90","unstructured":"Musa R, Rout P, Qurie A (2025) Lupus nephritis. In: StatPearls. StatPearls Publishing, Treasure Island (FL).\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499817\/"},{"key":"5549_CR91","doi-asserted-by":"publisher","unstructured":"Hailu G-MT, Hussen SU, Getachew S, Berha AB (2022) Management practice and treatment outcomes of adult patients with lupus nephritis at the Renal Clinic of St. Paul\u2019s Hospital Millennium Medical College, Addis Ababa, Ethiopia. BMC Nephrol. 23, 214 (2022). https:\/\/doi.org\/10.1186\/s12882-022-02846-z","DOI":"10.1186\/s12882-022-02846-z"},{"key":"5549_CR92","doi-asserted-by":"publisher","unstructured":"Mukerjee N, Maitra S, Gorai S, Ghosh A, Alexiou A, Thorat ND (2023) Revolutionizing human papillomavirus (HPV)-related cancertherapies: Unveiling the promise of proteolysis targeting chimeras (PROTACs) and Proteolysis Targeting Antibodies(PROTABs) in cancer nano-vaccines. J Med Virol 95(10):e29135.\u00a0https:\/\/doi.org\/10.1002\/jmv.29135","DOI":"10.1002\/jmv.29135"},{"key":"5549_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/ctd2.337","volume":"4","author":"S Maitra","year":"2024","unstructured":"Maitra S, Mukerjee N, Mukherjee D, Ghosh A, Alexiou AT (2024) Proteolysis targeting chimeras: a new cutting-edge nanomedicine for colorectal cancer. Clin Transl Discov 4:e337. https:\/\/doi.org\/10.1002\/ctd2.337","journal-title":"Clin Transl Discov"},{"key":"5549_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00112-0","volume":"3","author":"Z Liu","year":"2022","unstructured":"Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, Chen Y, Fan L, et al. (2022) An overview of PROTACs: a promising drug discovery paradigm. Mol Biomed 3:46. https:\/\/doi.org\/10.1186\/s43556-022-00112-0","journal-title":"Mol Biomed"},{"key":"5549_CR95","doi-asserted-by":"publisher","first-page":"22268","DOI":"10.1021\/acsomega.3c00205","volume":"8","author":"VA Adhav","year":"2023","unstructured":"Adhav VA, Saikrishnan K (2023) The realm of unconventional noncovalent interactions in proteins: their significance in structure and function. ACS Omega 8:22268\u201322284. https:\/\/doi.org\/10.1021\/acsomega.3c00205","journal-title":"ACS Omega"},{"key":"5549_CR96","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","volume":"27","author":"DA Nalawansha","year":"2020","unstructured":"Nalawansha DA, Crews CM (2020) PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem Biol 27:998\u20131014. https:\/\/doi.org\/10.1016\/j.chembiol.2020.07.020","journal-title":"Cell Chem Biol"},{"key":"5549_CR97","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther 7:113. https:\/\/doi.org\/10.1038\/s41392-022-00966-4","journal-title":"Signal Transduct Target Ther"},{"key":"5549_CR98","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/pharmaceutics15020411","volume":"15","author":"Y Moon","year":"2023","unstructured":"Moon Y, Jeon SI, Shim MK, Kim K (2023) Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy. Pharmaceutics 15:411. https:\/\/doi.org\/10.3390\/pharmaceutics15020411","journal-title":"Pharmaceutics"},{"issue":"15","key":"5549_CR99","doi-asserted-by":"publisher","first-page":"1392546","DOI":"10.3389\/fimmu.2024.1392546","volume":"4","author":"X Ren","year":"2024","unstructured":"Ren X, Wang L, Liu L, Liu J (2024) PTMs of PD-1\/PD-L1 and PROTACs application for improving cancer immunotherapy. Front Immunol 4(15):1392546. https:\/\/doi.org\/10.3389\/fimmu.2024.1392546","journal-title":"Front Immunol"},{"key":"5549_CR100","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","volume":"21","author":"X Li","year":"2022","unstructured":"Li X, Pu W, Zheng Q, Ai M, Chen S, Peng Y (2022) Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol Cancer 21:99. https:\/\/doi.org\/10.1186\/s12943-021-01434-3","journal-title":"Mol Cancer"},{"key":"5549_CR101","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-h","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807\u2013815. https:\/\/doi.org\/10.1016\/0092-8674(91)90124-h","journal-title":"Cell"},{"issue":"3","key":"5549_CR102","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.5958\/0974-360X.2019.00239.7","volume":"12","author":"S Shenuka","year":"2019","unstructured":"Shenuka S, Thiyagarajan T, Kumar RS (2019) A review on the effect of immunosuppressants on fertility. Res J Pharm Technol 12(3):1441\u20137. https:\/\/doi.org\/10.5958\/0974-360X.2019.00239.7","journal-title":"Res J Pharm Technol"},{"key":"5549_CR103","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/diagnostics15131648","volume":"15","author":"R Kumar","year":"2025","unstructured":"Kumar R, Marla K, Sporn K, Paladugu P, Khanna A, Gowda C, Ngo A, Waisberg E, et al. (2025) Emerging diagnostic approaches for musculoskeletal disorders: advances in imaging, biomarkers, and clinical assessment. Diagnostics 15:1648. https:\/\/doi.org\/10.3390\/diagnostics15131648","journal-title":"Diagnostics"},{"key":"5549_CR104","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11547-019-01035-7","volume":"124","author":"F Bruno","year":"2019","unstructured":"Bruno F, Arrigoni F, Mariani S, Splendiani A, Di Cesare E, Masciocchi C, Barile A (2019) Advanced magnetic resonance imaging (MRI) of soft tissue tumors: techniques and applications. Radiol Med 124:243\u2013252. https:\/\/doi.org\/10.1007\/s11547-019-01035-7","journal-title":"Radiol Med"},{"key":"5549_CR105","doi-asserted-by":"publisher","first-page":"5164970","DOI":"10.1155\/2022\/5164970","volume":"2022","author":"S Hussain","year":"2022","unstructured":"Hussain S, Mubeen I, Ullah N, Shah SSUD, Khan BA, Zahoor M, Ullah R, Khan FA, et al. (2022) Modern diagnostic imaging technique applications and risk factors in the medical field: a review. BioMed Res Int 2022:5164970. https:\/\/doi.org\/10.1155\/2022\/5164970","journal-title":"BioMed Res Int"},{"key":"5549_CR106","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.4103\/1319-2442.352443","volume":"32","author":"A Ullah","year":"2021","unstructured":"Ullah A, Aly A, Ali T, Alahmadi I (2021) Calcineurin inhibitor-induced pain syndrome: an uncommon but a debilitating complication of calcineurin inhibitors use. Saudi J Kidney Dis Transpl 32:1795\u20131799. https:\/\/doi.org\/10.4103\/1319-2442.352443","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"5549_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03076-2","volume":"21","author":"Y Shi","year":"2023","unstructured":"Shi Y, Wu W (2023) Multimodal non-invasive non-pharmacological therapies for chronic pain: mechanisms and progress. BMC Med 21:372. https:\/\/doi.org\/10.1186\/s12916-023-03076-2","journal-title":"BMC Med"},{"key":"5549_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17050619","volume":"17","author":"P Barriga-Rodr\u00edguez","year":"2025","unstructured":"Barriga-Rodr\u00edguez P, Falc\u00f3n-Cubillo M, Mej\u00edas-Trueba M, Ciudad-Guti\u00e9rrez P, Guisado-Gil AB, G\u00f3mez-Bravo M\u00c1, Porras-L\u00f3pez M, Gil-Navarro MV, et al. (2025) Pharmacokinetics of different tacrolimus formulations in the early post-liver transplant period: a scoping review. Pharmaceutics 17:619. https:\/\/doi.org\/10.3390\/pharmaceutics17050619","journal-title":"Pharmaceutics"},{"key":"5549_CR109","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.2174\/1570159X22666231017141636","volume":"22","author":"JV Garmendia","year":"2024","unstructured":"Garmendia JV, De Sanctis CV, Das V, Annadurai N, Hajduch M, De Sanctis JB (2024) Inflammation, autoimmunity and neurodegenerative diseases, therapeutics and beyond. Curr Neuropharmacol 22:1080\u20131109. https:\/\/doi.org\/10.2174\/1570159X22666231017141636","journal-title":"Curr Neuropharmacol"},{"issue":"7","key":"5549_CR110","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fimmu.2016.00116","volume":"7","author":"H Pan","year":"2016","unstructured":"Pan H, Gazarian A, Dubernard JM, Belot A, Michallet MC, Michallet M (2016) Transplant tolerance induction in newborn infants: mechanisms, advantages, and potential strategies. Front Immunol 7(7):116. https:\/\/doi.org\/10.3389\/fimmu.2016.00116","journal-title":"Front Immunol"},{"key":"5549_CR111","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3390\/jcm14072364","volume":"14","author":"G Gomez-Casado","year":"2025","unstructured":"Gomez-Casado G, Alonso-Titos J, Gonzalez-Mesa E, Ortega-Gomez A (2025) Compatibility of post-kidney transplant immunosuppression therapy with lactation. J Clin Med 14:2364. https:\/\/doi.org\/10.3390\/jcm14072364","journal-title":"J Clin Med"},{"key":"5549_CR112","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40620-025-02296-4","volume":"38","author":"D Anglicheau","year":"2025","unstructured":"Anglicheau D, Durrbach A, Bardoulat I, Arnaud M, Cott\u00e9 F-E, Vadanici R, Chartier M, Glotz D (2025) Immunosuppressive treatment patterns in kidney transplant recipients in France: an insurance claims database study (OISTER) over a 12 year period. J Nephrol 38:1229\u20131237. https:\/\/doi.org\/10.1007\/s40620-025-02296-4","journal-title":"J Nephrol"},{"key":"5549_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy10050106","volume":"10","author":"TO Aremu","year":"2022","unstructured":"Aremu TO, Oluwole OE, Adeyinka KO, Schommer JC (2022) Medication adherence and compliance: recipe for improving patient outcomes. Pharmacy (Basel) 10:106. https:\/\/doi.org\/10.3390\/pharmacy10050106","journal-title":"Pharmacy (Basel)"},{"key":"5549_CR114","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s44411-025-00227-0","volume":"126","author":"P Schnorrerova","year":"2025","unstructured":"Schnorrerova P, Matalova P, Wawruch M (2025) Medication adherence and intervention strategies: why should we care. Bratisl Med J 126:1196\u20131206. https:\/\/doi.org\/10.1007\/s44411-025-00227-0","journal-title":"Bratisl Med J"},{"key":"5549_CR115","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1093\/ejendo\/lvaf182","volume":"193","author":"T Diker Cohen","year":"2025","unstructured":"Diker Cohen T, Dotan I, Calvarysky B, Robenshtok E (2025) Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients. Eur J Endocrinol 193:R1\u2013R16. https:\/\/doi.org\/10.1093\/ejendo\/lvaf182","journal-title":"Eur J Endocrinol"},{"key":"5549_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1394553","author":"S Miao","year":"2024","unstructured":"Miao S, Yang M, Li W, Yang Z, Yan J (2024) Efficacy and safety of calcineurin inhibitors (CNIs) for septic patients in ICU: a cohort study from MIMIC database. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1394553","journal-title":"Front Pharmacol"},{"key":"5549_CR117","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/14622416.2024.2370761","volume":"25","author":"SA Hussaini","year":"2024","unstructured":"Hussaini SA, Waziri B, Dickens C, Duarte R (2024) Pharmacogenetics of calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review. Pharmacogenomics 25:329. https:\/\/doi.org\/10.1080\/14622416.2024.2370761","journal-title":"Pharmacogenomics"},{"key":"5549_CR118","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/biomedicines8040094","volume":"8","author":"M Saiz-Rodr\u00edguez","year":"2020","unstructured":"Saiz-Rodr\u00edguez M, Almenara S, Navares-G\u00f3mez M, Ochoa D, Rom\u00e1n M, Zubiaur P, Koller D, Santos M, et al. (2020) Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines 8:94. https:\/\/doi.org\/10.3390\/biomedicines8040094","journal-title":"Biomedicines"},{"key":"5549_CR119","doi-asserted-by":"publisher","unstructured":"Oates JT, Lopez D (2018) Pharmacogenetics: an important part of drug development with a focus on its application. International journal of biomedical investigation 1(2):111. https:\/\/doi.org\/10.31531\/2581-4745.1000111","DOI":"10.31531\/2581-4745.1000111"},{"key":"5549_CR120","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/nep.14035","volume":"27","author":"CY Cheung","year":"2022","unstructured":"Cheung CY, Tang SCW (2022) Personalized immunosuppression after kidney transplantation. Nephrology 27:475\u2013483. https:\/\/doi.org\/10.1111\/nep.14035","journal-title":"Nephrology"},{"key":"5549_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/jof9040464","volume":"9","author":"NN Vuong","year":"2023","unstructured":"Vuong NN, Hammond D, Kontoyiannis DP (2023) Clinical uses of inhaled antifungals for invasive pulmonary fungal disease: promises and challenges. J Fungi 9:464. https:\/\/doi.org\/10.3390\/jof9040464","journal-title":"J Fungi"},{"key":"5549_CR122","unstructured":"Leas BF, Uhl S, Sawinski DL, Trofe-Clark J, Tuteja S, Kaczmarek JL, Umscheid CA (2016) Calcineurin inhibitors for renal transplant. Agency for Healthcare Research and Quality (US), Rockville (MD). https:\/\/pubmed.ncbi.nlm.nih.gov\/27123504\/"},{"key":"5549_CR123","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, et al. (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22:1945\u20131960. https:\/\/doi.org\/10.1002\/ejhf.1920","journal-title":"Eur J Heart Fail"},{"key":"5549_CR124","doi-asserted-by":"publisher","unstructured":"Hadjari M, Bereksi K (2023) Lipid Profile, Renal Function Tests and Inflammatory Markers in Algerian Type 2 Diabetic Patients. Iranian Journal of Public Health 52(4):732. https:\/\/doi.org\/10.18502\/ijph.v52i4.12441","DOI":"10.18502\/ijph.v52i4.12441"},{"key":"5549_CR125","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","volume":"25","author":"VM Pratt","year":"2023","unstructured":"Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, et al. (2023) CYP3A4 and CYP3A5 genotyping recommendations. J Mol Diagn JMD 25:619\u2013629. https:\/\/doi.org\/10.1016\/j.jmoldx.2023.06.008","journal-title":"J Mol Diagn JMD"},{"key":"5549_CR126","doi-asserted-by":"publisher","unstructured":"Xajil-Ramos LY, G\u00e1ndara-Mireles JA, Vargas Rosales RJ, S\u00e1nchez Garc\u00eda OK, Ruano Toledo AM, Aldana de la Cruz AK, Lares-Asseff I, Patr\u00f3n-Romero L, Almanza-Reyes H, Lou-Meda R. Impact of CYP3A5 1 and 3 single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients. Frontiers in Pharmacology. 2025 May 13;16:1592134. https:\/\/doi.org\/10.3389\/fphar.2025.1592134","DOI":"10.3389\/fphar.2025.1592134"},{"key":"5549_CR127","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/dme.13810","volume":"36","author":"JA Hirst","year":"2019","unstructured":"Hirst JA, Farmer AJ, Smith MC, Stevens RJ (2019) Timings for HbA1c testing in people with diabetes are associated with incentive payments: an analysis of UK primary care data. Diabet Med 36:36\u201343. https:\/\/doi.org\/10.1111\/dme.13810","journal-title":"Diabet Med"},{"key":"5549_CR128","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.2146\/ajhp110624","volume":"69","author":"R-A Lee","year":"2012","unstructured":"Lee R-A, Gabardi S (2012) Current trends in immunosuppressive therapies for renal transplant recipients. Am J Health-Syst Pharm 69:1961\u20131975. https:\/\/doi.org\/10.2146\/ajhp110624","journal-title":"Am J Health-Syst Pharm"},{"key":"5549_CR129","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s43441-023-00599-x","volume":"58","author":"N Antognini","year":"2024","unstructured":"Antognini N, Portman R, Dong V, Webb NJ, Chand DH (2024) Detection, monitoring, and mitigation of drug-induced nephrotoxicity: a pragmatic approach. Ther Innov Regul Sci 58:286\u2013302. https:\/\/doi.org\/10.1007\/s43441-023-00599-x","journal-title":"Ther Innov Regul Sci"},{"key":"5549_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11278","volume":"8","author":"KA Patel","year":"2022","unstructured":"Patel KA, Bhatt MH, Hirani RV, Patel VA, Patel VN, Shah GB, Chorawala MR (2022) Assessment of potential drug\u2013drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study). Heliyon 8:e11278. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11278","journal-title":"Heliyon"},{"key":"5549_CR131","doi-asserted-by":"publisher","unstructured":"Borges RD, Degobi NA, Bertoluci MC (2020) Choosing statins: a review to guide clinical practice. Archives of endocrinology and metabolism 64:639-53. https:\/\/doi.org\/10.20945\/2359-3997000000306","DOI":"10.20945\/2359-3997000000306"},{"key":"5549_CR132","unstructured":"Simon LV, Hashmi MF, Farrell MW (2025) Hyperkalemia. In: StatPearls. StatPearls Publishing, Treasure Island (FL).\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470284\/"},{"key":"5549_CR133","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1681\/ASN.2017111163","volume":"29","author":"AN Harris","year":"2018","unstructured":"Harris AN, Grimm PR, Lee H-W, Delpire E, Fang L, Verlander JW, Welling PA, Weiner ID (2018) Mechanism of hyperkalemia-induced metabolic acidosis. J Am Soc Nephrol 29:1411\u20131425. https:\/\/doi.org\/10.1681\/ASN.2017111163","journal-title":"J Am Soc Nephrol"},{"key":"5549_CR134","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CIN.0000000000000683","volume":"39","author":"JA Thate","year":"2020","unstructured":"Thate JA, Couture B, Schnock KO, Rossetti SC (2020) Information needs and the use of documentation to support collaborative decision-making. CIN-Comput Inform Nurs 39:208\u2013214. https:\/\/doi.org\/10.1097\/CIN.0000000000000683","journal-title":"CIN-Comput Inform Nurs"},{"key":"5549_CR135","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ckj\/sfac232","volume":"16","author":"YL Kaufmann","year":"2022","unstructured":"Kaufmann YL, von Moos S, Spitznagel T, Matter LS, Mueller TF, Schachtner T (2022) Collaboration between local nephrologists and the transplant centre ensures good outcomes in post-transplant care. Clin Kidney J 16:331\u2013341. https:\/\/doi.org\/10.1093\/ckj\/sfac232","journal-title":"Clin Kidney J"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05549-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05549-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05549-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:20:27Z","timestamp":1765293627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05549-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5549"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05549-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"17 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"275"}}